Literature DB >> 7690241

The CR2/CD19 complex on human B cells contains the src-family kinase Lyn.

C J van Noesel1, A C Lankester, G M van Schijndel, R A van Lier.   

Abstract

The complement receptor 2 (CR2 or CD21) can be found in non-covalent association with the B lymphocyte specific CD19 complex at the surface of mature human B cells. Upon ligation of the B cell antigen receptor complex (BCR), members of the CR2-CD19 complex may associate with membrane immunoglobulin (mlg). Moreover, CD19 and CD21 ligands, either murine mAb, C3d fragments or Epstein-Barr virus, are known to have profound effects on B cell activation. We here show that CD19 is tightly linked to the non-receptor src kinase Lyn and that the CD19 glycoprotein itself serves as a substrate for a yet undefined serine/threonine kinase present within the complex. In the process of antigen recognition, mlg and the CR2-CD19 complex may bind different sites of a complement-opsonized antigenic particle. We hypothesize that in this process, approximation to the BCR allows CD19-associated Lyn kinase to phosphorylate potential substrates within the antigen-receptor complex, thereby effecting its coupling to the intracellular compartment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690241     DOI: 10.1093/intimm/5.7.699

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  14 in total

Review 1.  The role of complement in the acquired immune response.

Authors:  C H Nielsen; E M Fischer; R G Leslie
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

Review 2.  Combination of celecoxib (Celebrex®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.

Authors:  Tam Nm Dinh; Alexandra S Onea; Ali R Jazirehi
Journal:  Am J Clin Exp Immunol       Date:  2017-05-15

Review 3.  CD19 function in central and peripheral B-cell development.

Authors:  Christopher J Del Nagro; Dennis C Otero; Amy N Anzelon; Sidne A Omori; Ravi V Kolla; Robert C Rickert
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

4.  Epstein-Barr virus latent membrane protein 2A preferentially signals through the Src family kinase Lyn.

Authors:  Mark Rovedo; Richard Longnecker
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

5.  Lyn tyrosine kinase signals cell cycle arrest but not apoptosis in B-lineage lymphoma cells.

Authors:  R H Scheuermann; E Racila; T Tucker; E Yefenof; N E Street; E S Vitetta; L J Picker; J W Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

6.  The CD19/CD81 complex physically interacts with CD38 but is not required to induce proliferation in mouse B lymphocytes.

Authors:  Felipe Vences-Catalán; Ranjani Rajapaksa; Shoshana Levy; Leopoldo Santos-Argumedo
Journal:  Immunology       Date:  2012-09       Impact factor: 7.397

7.  The 3BP2 adapter protein is required for optimal B-cell activation and thymus-independent type 2 humoral response.

Authors:  Grace Chen; Ioannis D Dimitriou; Jose La Rose; Subburaj Ilangumaran; Wen-Chen Yeh; Gina Doody; Martin Turner; Jennifer Gommerman; Robert Rottapel
Journal:  Mol Cell Biol       Date:  2007-02-05       Impact factor: 4.272

Review 8.  CD19 regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive amplification.

Authors:  M Fujimoto; J C Poe; M Hasegawa; T F Tedder
Journal:  Immunol Res       Date:  2000       Impact factor: 4.505

9.  Qualitative regulation of B cell antigen receptor signaling by CD19: selective requirement for PI3-kinase activation, inositol-1,4,5-trisphosphate production and Ca2+ mobilization.

Authors:  A M Buhl; C M Pleiman; R C Rickert; J C Cambier
Journal:  J Exp Med       Date:  1997-12-01       Impact factor: 14.307

10.  CD16-mediated p21ras activation is associated with Shc and p36 tyrosine phosphorylation and their binding with Grb2 in human natural killer cells.

Authors:  R Galandrini; G Palmieri; M Piccoli; L Frati; A Santoni
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.